Travis Johnson, Stock Gumshoe

Author Bio

Travis Johnson, Stock Gumshoe
Travis Johnson is an individual investor who founded Stock Gumshoe in 2007 as a way to air his dissections of overhyped marketing pitches... and to share the "secret" stocks that stock newsletters hype to get your attention and your subscription dollars. His thinking? If you already know what the "secret" stock is, you can make a much more reasonable and thoughtful decision about whether or not to commit to an expensive newsletter subscription. (And if you don't pay for the info, you'll be more free to think for yourself about whether or not the investment is worth your money.) In his charmed life he has been, among other things, a university faculty member, a fundraiser, a writer, and a world-champion ice-cream scooper. Now he runs Stock Gumshoe for you, allowing us all to discuss and dissect the latest overheated stock ideas... as well as review and talk about investment newsletters and enjoy the commentary and opinions of Stock Gumshoe's other special contributors and the discussion with our unusually attractive, erudite and polite readers. He lives with Mrs. Gumshoe and all their little Gumshoes in the wilds of Western Massachusetts.

Author Archives

“Day Zero” — What’s Jeff Siegel talking about when he says, “November 13th, 2019 will be the most profitable day in the history of mankind.”

This article was originally published on March 21, 2019 when the “deadline” touted was March 25. We’ve lightly updated our piece below, but much of it (like the ad) is unchanged from March. The latest ad for Green Chip Stocks is a doozy — reminiscent of the many “the world is about to change” ads […]

Investing Whisperer

Small-cap stock picking service from Keith Schaefer in 2019 — he has run an energy focused newsletter for a decade or so (Oil and Gas Investments Bulletin), but this one is an “all sector” product. Aims to recommend 6-12 stocks a year, often really tiny companies, with a portfolio of 5-15 stocks at any one […]

“The #1 Penny Stock of 2020” teased by Paradigm… “It holds the $8.18 Trillion Cure to Man’s Biggest Problem”

Hard to believe that the major publishers didn’t already have something called The Penny Stock Letter, but this is the first time I’ve seen the title — it’s an entry-level newsletter from Paradigm Press, one of the many publishers in the Baltimore Agoraplex, and they’re promoting it with a big teaser campaign now that hints […]

Friday File: REIT Beat and More

A pretty quiet week as I try not to overreact to market gyrations, so we’ll be briefer than usual this Friday… but there are a few interesting things to talk about…. Crown Castle (CCI) reported a “beat and raise” quarter this week, if just barely. They raised their dividend roughly as expected this week, bumping […]

“1+1=4” and “The Universal Cancer Cure” — What’s Stansberry’s Dave Lashmet talking about in his latest ads?

Dave Lashmet has been a biotech/medical analyst and sometimes a newsletter editor at Stansberry for a long time, and the latest iteration of his high-end newsletter is now called Stansberry Venture Technology (currently “on sale” for $2,500, no refunds)… and it’s now being promoted with a “cure for cancer” spiel, so we obviously all want […]

“America’s Most ‘Stupid’ Family”

No, this one’s not about you and your Uncle Bill. And it’s not about the little Gumshoes and their struggle with Algebra. It’s a headline from Frank Curzio, who earlier in the week sent out a hint-y email to at least a few folks that said, “How to capitalize on America’s most ‘stupid’ family.” It’s […]

Friday File: Marijuana Burning

Innovative Industrial Properties (IIPR) hit a stop loss yesterday thanks to a sector-wide collapse of marijuana stocks. The big news that hits IIPR directly this week was that MedMen dropped its plan to buy PharmaCann, which is IIPR’s biggest tenant, so I did take the somewhat cautious step of buying a few protective puts just […]

High Alpha

Monthly newsletter providing small-cap stock recommendations aimed at individual investors, recommendations are based on “hidden value” he sees using the UAFRS accounting adjustments developed by his Valens Research company for institutional subscribers.

Recent Author Comments

On "The #1 Penny Stock of 2020" teased by Paradigm... "It holds the $8.18 Trillion Cure to Man’s Biggest Problem"
Since we're talking about "man's biggest problem" and the power of marketing and groupthink, I should have included my favorite quote: "All of humanity's problems stem from man's inability to sit quietly in a room alone." - Blaise Pascal[...]
On What's Schaefer's "The Next Uber: The Backdoor Way to Profit from the Rideshare Revolution?"
Indeed... and autonomous cars are really the only thing that gives Uber or Lyft any hope of scalability (they've already pressured their drivers probably too much, so there isn't any margin to be gained otherwise unless they can raise their prices a lot).[...]
On What's Schaefer's "The Next Uber: The Backdoor Way to Profit from the Rideshare Revolution?"
Good points Gary, thanks.[...]
On "America's Most 'Stupid' Family"
All the "Chiefs" -- titles with "C" in them, like CEO, CFO, COO.[...]
On Sleuthifying Cabot's "U.S.-China rivalry will soon send this secret $1 stock soaring" Pitch
Ha! Good one...[...]
On "The #1 Penny Stock of 2020" teased by Paradigm... "It holds the $8.18 Trillion Cure to Man’s Biggest Problem"
Lots of anecdotal evidence for THC and CBD in various types of pain management, though certainly not without side effects... and anecdotes have to be taken with a grain of salt when it comes to something like pain, where placebos often have a huge effect a[...]
On Friday File: REIT Beat and More
Nothing new this week that changed my thinking.[...]
On Friday File: REIT Beat and More
I believe 10/28 is the record date, but 10/25 is the day that it begins trading without rights to that next dividend (after you buy a stock, it takes a couple days for you to actually become the owner of record). The money actually hits your account a few[...]
On Motley Fool's "Like Buying McDonald's in 1965" Stock
Good question. XLRE has done substantially better than VNQ recently, probably mostly because it has more weighting in the booming tower stocks (24% vs. 11% or so).[...]
On "1+1=4" and "The Universal Cancer Cure" -- What's Stansberry's Dave Lashmet talking about in his latest ads?
Interestingly enough, a day after I write about Innate Pharma they price their Nasdaq listing/IPO at a steep discount -- they're raising something like $70 million at US$5.50, and will soon trade on the Nasdaq at IPHA. Presumably that heavily discounted s[...]
On Unpacking Leeb's "Devastating 5G Flaw Exposed" Teaser Pitch
Sure, but if I recall correctly the Gates Foundation bought their CCI shares many, many years ago.[...]
On "1+1=4" and "The Universal Cancer Cure" -- What's Stansberry's Dave Lashmet talking about in his latest ads?
Lynn's putting them together now, I haven't had a chance to read them but we should know soon. Thanks for all the submissions, folks![...]
On Microblog: Dan Ferris - Post FAANG strategies The Unwind
Haven't seen any detail in those teasers, but chemical companies in general are in the "cheap and hated" category at the moment so I suspect the reader is referring to one or more of the Dow-DuPont breakup companies -- which will be Dow (DOW), DuPont (DD),[...]
On "Image Mapping Rollout" to cure "3rd Leading Cause of Death?"
Thanks, we're thinking of ways to make the summaries more accessible. For financial data I like YCharts, though the free version is limited.[...]
On "America's Most 'Stupid' Family"
No, mostly just the Chanel folks (plus the CEO, a little). Most research I’ve seen has shown that multiple C-suite buys are the strongest positive indicators for the stock price (and that the good impact tends to be 6-18 months after insider purchases[...]
On Motley Fool's "Like Buying McDonald's in 1965" Stock
I expect that's AMT again, but will try to have a look.[...]
On "Image Mapping Rollout" to cure "3rd Leading Cause of Death?"
We've got a little contest going on for some free memberships, ends today -- details:[...]
On "Image Mapping Rollout" to cure "3rd Leading Cause of Death?"
I assume there will be, eventually, but this is all super early.[...]
On "Image Mapping Rollout" to cure "3rd Leading Cause of Death?"
I do find some stocks that I like, and sometimes I buy them, either when I first write about it or months or years later when I get more comfortable with them. I like to think that I'm usually able to separate my idea of a company's future from the almost[...]
On "Image Mapping Rollout" to cure "3rd Leading Cause of Death?"
Probably true... but if your only concern is "the technology isn't quite good enough yet" you can be sure, at least, that it will improve.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch